Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.
about
A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brainNovel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?Innovations in phenotyping of mouse models in the German Mouse Clinic.MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.A cross-species analysis method to analyze animal models' similarity to human's disease state.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate CancerRecent Advances and New Strategies in Targeting Plk1 for Anticancer TherapySelective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domainQuantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Current assessment of polo-like kinases as anti-tumor drug targets.The role of Plk3 in oncogenesis.Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state.pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cellsGenetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8.Sequential Cdk1 and Plk1 phosphorylation of caspase-8 triggers apoptotic cell death during mitosisFcγRIIb on liver sinusoidal endothelium clears small immune complexes.Mitotic Kinases and p53 Signaling.Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells.The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.Polo-like kinases in AML.PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics.A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptorPolo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma
P2860
Q27304385-4BAC0B5D-A558-4561-AB2A-EE9DABE93B19Q27684872-75ECDF00-5F2C-468A-A0DB-5ABA48714A41Q28262425-1C270BE3-EDD2-4F05-9D55-795BD66E0010Q30485660-CF3ED74A-4CCE-4469-8C25-D352D89ED951Q34476639-2D4B3924-A3AA-4D7B-B7D5-AC956C4225FCQ34530293-9ADD1081-51DF-48D5-851F-A1202D7FDBE5Q36062154-66243E93-B2C5-40AA-8988-17939FD1E13DQ36289531-2EC51BD0-D323-4DA6-A440-48C74241A7C5Q36386336-F7ADF959-9F40-4860-BABA-B1EEA0193672Q36781191-7AD2E8B2-4226-47FB-AF7E-C22E56BF7155Q37302721-EC54217A-8840-44A1-82AC-7C2C24C77DDBQ37398885-BEB91EC3-CC37-416C-AC34-0C3105513A22Q37994256-600DB6C8-4283-423A-8D82-FA682BB36A52Q38129174-CA985550-26E0-4759-809D-519406ED07CCQ38211244-B428EBB3-C804-4BAC-89CB-861A68AA827BQ38444150-A596C242-280C-4EF0-ABA0-5576C625FC65Q38718733-71E40D6E-4757-4ABF-B51B-BA7F15F9F358Q38842267-AE9AB051-B437-46BE-B1F5-C8101685D89EQ38961886-332602CE-1BDE-413B-8133-2FD88B03E5E2Q38973171-70500682-B3C6-4D28-B144-76CA3F8A55A3Q39042925-17575B2E-1573-45D3-80DE-0ADBE15A7064Q39141522-66C23C26-283A-48EF-87C4-039847D0AEECQ39601527-D17CF981-66D1-4E27-9D6C-722B00D6B1EDQ39668561-82E049AF-F217-4AB9-A822-09F397D5798CQ41135486-07711612-8959-4251-AD1B-F40ED09A621BQ41888418-3E0036F9-A707-4FC3-88EF-265F657F5110Q42254103-3B1C59A6-4759-4BC1-986F-E1BAF2A9E4B5Q42329961-C904E9CC-7AE0-4A8F-9E79-5882C61E7A03Q42777655-00F3F48E-F76C-4F08-A30A-35A40AE718D5Q42858044-6D9D383A-D5FD-4186-8622-70E001EFFD06Q45068538-9DC5A619-C2EF-4522-9359-B47FFE683069Q46455146-F0FFAA38-5BBD-473B-AD2B-D9DB4CC5A336Q50939437-6239B74D-58F6-4800-8418-E70E5E35AC24Q52352270-BF47C48B-E1C5-4133-9E53-3D7879609035Q53015871-F9EC1719-9235-465E-86DF-445CF4F1DDDFQ55054132-2234AC51-74D6-4B2A-9AFA-836D04E803DEQ57809711-D4E98F81-8CF0-4046-8136-B9E4F5AF3B38Q58920117-45F21E0E-25B0-44CA-B0B6-102F34EC2DBE
P2860
Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@ast
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@en
type
label
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@ast
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@en
prefLabel
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@ast
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@en
P2093
P2860
P50
P356
P1476
Toxicity modelling of Plk1-tar ...... tured primary mammalian cells.
@en
P2093
Andrea Krämer
Bertolt Kreft
Birgit Rathkolb
Dirk H Busch
Elisabeth Kurunci-Csacsko
Florian Prinz
Helmut Fuchs
Jost Seibler
Juping Yuan
Klaus Strebhardt
P2860
P2888
P356
10.1038/NCOMMS1395
P407
P50
P577
2011-07-19T00:00:00Z